Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
01 February 2019 | Story Zama Feni | Photo Charl Devenish
Disease Control and Prevention InStory
From left, seated: Dr Mathew Esona, CDC delegate; Dr Michael Bowen, CDC delegate; Dr Martin Nyaga, lead Researcher at the UFS-NGS Unit; standing: Mojalefa Buti, Office of the Vice-Dean, UFS Faculty of Health Sciences; Dr Glen Tylor, Senior Director, Directorate Research Development; Cornelius Hagenmeier, Director, Office for International Affairs; and Dr Saheed Sabiu, Postdoctoral Research Fellow in the Faculty of Natural and Agricultural Sciences.

In pursuit of efforts to advance research on viruses and disease control, the United States-based Centre for Disease Control and Prevention (CDC) has made a commitment to enhance the University of the Free State (UFS) Next Generation Sequencing (NGS) Unit’s data collection systems and further empower its staff and students.

UFS and US guests explore areas of mutual; cooperation

During a visit to the university in early December last year CDC delegation, Dr Michael Bowen and Dr Mathew Esona, a meeting was held with the lead Researcher at the UFS-NGS Unit, Dr Martin Nyaga; Senior Director of the UFS Directorate Research Development, Dr Glen Tylor; Director of UFS Office for International Affairs, Cornelius Hagenmeier; and Dr Saheed Sabiu Postdoctoral Research Fellow in the Faculty of Natural and Agriculture Sciences. It was in this meeting that areas of mutual collaboration and engagement between the two institutions which include technology transfer, funding and wet and dry laboratory quality control and capacity development were identified.

The UFS-NGS Unit, established in 2016, enjoys longstanding networking and collaborative ventures with renowned researchers in Africa, the USA, and Europe – which in return, have contributed immensely to the research activities of the university as a whole.

Dr Nyaga said in an effort to advance genomics research in the NGS Unit, the visitors have committed themselves to initiate and further enhance capacity development for the unit’s staff and students.

US guests impressed with advanced equipment at UFS

The CDC delegation were intrigued that the UFS also operates a Miseq Illumina platform like the one used at their enteric-viruses laboratory. It could thus be in line to assist in developing exclusive pipelines for the analysis of NGS data generated by the UFS-NGS Unit.

This is a personal sequencing system, which is a powerful state-of-the-art next-generation sequencer. It uses sequencing-by-synthesis technology capable of sequencing up to 15GB of high-quality filtered bases per run, with up to 600 base-pair read lengths. This allows the assembly of small genomes or the detection of target variants with unmatched accuracy, especially within homo-polymer regions.

UFS and CDC engagements still on

Further engagements about the identified areas of collaboration are ongoing between Hagenmeier, Dr Bowen, and Dr Nyaga, who are currently working on appropriate mechanisms to enact the envisaged collaboration between the two institutions.

The NGS Unit received research awards from the World Health Organisation, South African Medical Research Council, Poliomyelitis Research Foundation, and the National Research Foundation for different aspects of genomics research, and more recently from the Bill and Melinda Gates Foundation for the Enteric Viruses Genome Initiative, involving four African countries (South Africa, Ghana, Malawi, and Cameroon).

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept